Publication:
A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus

dc.contributor.authorWanwisa Dejnirattisaien_US
dc.contributor.authorWiyada Wongwiwaten_US
dc.contributor.authorSunpetchuda Supasaen_US
dc.contributor.authorXiaokang Zhangen_US
dc.contributor.authorXinghong Daien_US
dc.contributor.authorAlexander Rouvinskyen_US
dc.contributor.authorAmonrat Jumnainsongen_US
dc.contributor.authorCarolyn Edwardsen_US
dc.contributor.authorNguyen Than Ha Quyenen_US
dc.contributor.authorThaneeya Duangchindaen_US
dc.contributor.authorJonathan M. Grimesen_US
dc.contributor.authorWen Yang Tsaien_US
dc.contributor.authorChih Yun Laien_US
dc.contributor.authorWei Kung Wangen_US
dc.contributor.authorPrida Malasiten_US
dc.contributor.authorJeremy Farraren_US
dc.contributor.authorCameron P. Simmonsen_US
dc.contributor.authorZ. Hong Zhouen_US
dc.contributor.authorFelix A. Reyen_US
dc.contributor.authorJuthathip Mongkolsapayaen_US
dc.contributor.authorGavin R. Screatonen_US
dc.contributor.otherImperial College Londonen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherInstitut Pasteur, Parisen_US
dc.contributor.otherCNRS Centre National de la Recherche Scientifiqueen_US
dc.contributor.otherUniversity of California, Los Angelesen_US
dc.contributor.otherKhon Kaen Universityen_US
dc.contributor.otherUCLen_US
dc.contributor.otherThailand National Center for Genetic Engineering and Biotechnologyen_US
dc.contributor.otherWellcome Trust Centre for Human Geneticsen_US
dc.contributor.otherScience Divisionen_US
dc.contributor.otherUniversity of Hawaii at Manoa John A. Burns School of Medicineen_US
dc.contributor.otherUniversity of Melbourneen_US
dc.date.accessioned2018-11-23T10:21:26Z
dc.date.available2018-11-23T10:21:26Z
dc.date.issued2015-01-01en_US
dc.description.abstract© 2015 Nature America, Inc. Dengue is a rapidly emerging, mosquito-borne viral infection, with an estimated 400 million infections occurring annually. To gain insight into dengue immunity, we characterized 145 human monoclonal antibodies (mAbs) and identified a previously unknown epitope, the envelope dimer epitope (EDE), that bridges two envelope protein subunits that make up the 90 repeating dimers on the mature virion. The mAbs to EDE were broadly reactive across the dengue serocomplex and fully neutralized virus produced in either insect cells or primary human cells, with 50% neutralization in the low picomolar range. Our results provide a path to a subunit vaccine against dengue virus and have implications for the design and monitoring of future vaccine trials in which the induction of antibody to the EDE should be prioritized.en_US
dc.identifier.citationNature Immunology. Vol.16, No.2 (2015), 170-177en_US
dc.identifier.doi10.1038/ni.3058en_US
dc.identifier.issn15292916en_US
dc.identifier.issn15292908en_US
dc.identifier.other2-s2.0-84922947115en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/36166
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84922947115&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.titleA new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virusen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84922947115&origin=inwarden_US

Files

Collections